The Hulscher 2026 ivermectin-cancer study, claiming an 84.4% clinical benefit rate among cancer patients, faces significant scrutiny due to its observational design, self-reported data, and potential conflicts of interest related to its commercial backers. Anticancer Research issued an Expression of Concern regarding data reliability, necessitating cautious interpretation of its findings.
Is the 2026 Ivermectin Cancer Study Real Evidence or a Red Flag? A Critical Analysis of What Patients Need to Know
